Achillion Pharmaceuticals reports results re its novel small molecule factor D inhibitor, ACH-4471. “We are very encouraged by these data, which support our focus on developing potent, specific factor D inhibitor compounds,” said Milind Deshpande, Ph.D., President and CEO of Achillion … more

Alexion Pharmaceuticals reports interim data from a Phase 1/2 study of ALXN1210, an investigational, highly innovative longer-acting anti-C5 antibody, in patients with paroxysmal nocturnal hemoglobinuria; and, separately, interim results from a Phase 2 trial evaluating ALXN1007, a novel anti-inflammatory antibody targeting complement protein C5a, in patients with acute graft-versus-host disease of the lower GI tract. “We are pleased to have late-breaking data from two of our highly innovative, investigational complement inhibitors,” said Martin Mackay, Ph.D., Executive Vice President and Global Head of R&D at Alexion … more